World’s first research of novel antibody therapeutic in peanut allergic people utilizing the proprietary SEQ SIFTER™ antibody discovery platform now totally enrolled
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–IgGenix, Inc., a scientific stage biotechnology firm taking a revolutionary method to handle allergic and atopic ailments, immediately introduced that it has accomplished enrollment for its Part 1 scientific research of IGNX001. The ACCELERATE Peanut research is a randomized, double-blind, placebo-controlled, single-ascending dose research designed to guage the protection, tolerability, pharmacokinetics, and pharmacodynamics of IGNX001 in peanut allergic people. The ultimate participant was dosed on August 12, 2025.
“Finishing enrollment in our first-in-human research is a pivotal second for IgGenix and a big step ahead for the thousands and thousands of people residing with the each day menace of extreme allergic reactions,” mentioned Jessica Grossman, M.D., Chief Government Officer of IgGenix. “We’re deeply grateful to the individuals and scientific investigators whose contributions have been instrumental in advancing this necessary program.”
“It has been a tremendous staff effort, and we sit up for analyzing the ACCELERATE Peanut information. We anticipate sharing topline information from this research within the coming months,” added Derek Croote, Ph.D., Chief Technical Officer of IgGenix.
This Part 1 security information will assist place the corporate for additional research of this novel remedy in peanut allergic people.
About IGNX001
IGNX001 is a first-in-class, high-affinity, human IgG4 monoclonal antibody therapeutic designed to forestall allergic reactions attributable to unintended allergen publicity. By blocking the binding of peanut allergens to IgE antibodies, IGNX001 intends to be a secure, efficacious, and fast-acting therapeutic for the remedy of peanut allergy.
About IgGenix
IgGenix is a privately held antibody discovery and improvement firm taking a revolutionary method to handle allergy symptoms and atopic ailments. By the proprietary SEQ SIFTER™ discovery platform, developed from foundational analysis of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford College, IgGenix isolates and re-engineers totally human, high-affinity, allergen-specific antibodies designed to dam and stop the allergic cascade. By concentrating on frequent immunodominant allergens and their most necessary epitopes throughout the affected person inhabitants, IgGenix intends to deal with allergic pediatric and grownup sufferers alike throughout meals and environmental allergy symptoms. This novel method could stop life-threatening allergic reactions, saving lives and decreasing the fixed worry that impacts thousands and thousands of individuals residing with extreme allergy symptoms.
Contacts
For Investor Inquiries:
Jessica Grossman, MD
jgrossman@iggenix.com
